

## **PRESCRIBING INCENTIVE SCHEME 2013-14 FOR SOUTH EAST ESSEX CCGs**

### **CORE TARGETS FOR EACH PRACTICE:**

#### **1. Finance**

Practices to remain within budget. Adjustments made for increases in list size and high cost drugs in year.

- Forecast outturn and cost per ASTROPU graphs to be supplied each month

**15% of total reward**

#### **2. Antibacterials – Measured items per ASTRO PU from ePACT**

Reduce overall prescribing (below National average for 2012) and specifically reduce prescribing of quionlones, cephalosporins and co-amoxiclav to below CCG average for 2012.

- Measured over 12 months
- Graphs of 4 targets monthly.

**10% of total**

#### **3. Prescription Clerk - Training and audit**

Clerks to attend CCG Time to Learn session on repeat prescribing. Subsequent audit aimed at identifying waste through analgesics, creams, inhalers etc.

- Audit and changes in practice due to outcomes documented and submitted by March 2014

**15% of total**

#### **4. Respiratory prescribing - training and audit**

Respiratory nurses to attend local training regarding respiratory disease in conjunction with Essex University.

Audit to be completed identifying all patients prescribed high dose combination inhalers and actions to be taken submitted by 31<sup>st</sup> Oct 2013

- Re Audit, documented review and outcomes (no change, stepped down, prescription changed etc.) to be submitted by March 2014
- Graphs showing Inhaled Corticosteroid Net Ingredient Cost per Average Daily Quantity, Inhaled Corticosteroid Average Daily Quantity per STARPU and Bronchodilator Average Daily Quantity per STARPU, quarterly

**15% of total**

## 5. **Diabetes prescribing – audit**

CCG Audit to be completed identifying all patients on Gliptins, GLP1s and pioglitazone. Cross reference with NICE criteria for cost effective use of these medicines and record outcomes.

- Audit to be submitted by 31<sup>st</sup> Oct 2013
- Re Audit, documented review and outcomes (no change, targets not achieved, referred to diabetic service and outcome, prescription changed etc.) to be submitted by March 2014
- Graph of % these drugs against all antidiabetic prescribing quarterly  
**15% of total**

### **Individual practice targets (agree 3 per practice) 10% each**

## 6. **Lipid lowering - Measured % items from ePACT**

Simvastatin, Pravastatin and Atorvastatin to account for 90% or more of all statin and Ezetimibe prescribing

- Measured as 3 month average
- Comparative Graph supplied each month

## 7. **Nutrition prescribing - audit and measured % items from ePACT**

a) Practice to use CCG audit tools and nutrition guidelines (oral, infant, gluten free) in order to reduce inappropriate prescribing.

- Audit to be submitted by 31<sup>st</sup> Oct 2013
- Re Audit, documented review and outcomes (prescription inappropriate, target weight reached, prescription changed to 1<sup>st</sup> line product etc.) to be submitted by March 2014

b) 40% of all ONS to be prescribed as per formulary 1<sup>st</sup> line (Aymes<sup>®</sup> Shake, Fresubin<sup>®</sup> Powder Extra, Complian<sup>®</sup> Shake).

- Measured as 3 month average
- Comparative ONS graph supplied each month
- GF cakes and biscuits, soya formula and liquid feeds graphs also supplied each month

**Nutrition audit counts as 2 of the 3 targets i.e. 20%.**

## 8. **Ostomy prescribing - Measured cost per ASTRO PU from ePACT**

Reduce prescribing costs by switching accessories to products contained in the locally agreed formulary.

Review Quantities in line with CCG guidance and do not supply retrospective prescriptions to 3rd party companies.

- Measured as cost per ASTROPU over 3 months
- Comparative graph supplied each month

**9. Incontinence appliances - Measured cost per ASTRO PU from ePACT**

Reduce prescribing costs by switching to locally agreed formulary products, and checking appropriate quantities supplied

- Measured as cost per ASTROPU over 3 months
- Comparative graph supplied each month

**10. Pregabalin - Measured cost per ASTRO PU from ePACT**

Rationalise doses and reduce number of capsules patients are currently taking

- Measured as cost per ASTROPU over 3 months
- Comparative graph supplied each month

**11. Specials – Audit and action returned monthly**

Reduce prescribing costs by reviewing in line with Specials Formulary. Return outcome of monthly specials report.

- Measured as cost per ASTROPU over 3 months
- Comparative graph supplied each month

**12. Doxazosin slow release preparations - Measured % items from ePACT**

Review prescribing and switch to normal release doxazosin if drug still appropriate.

- Measured as 3 month average
- Comparative Graph supplied each month

**13. Venlafaxine XL - Measured % items from ePACT**

Ensure prescribing of most cost-effective brands, Tonpular XL Capsules, Venlalic XL tablets, and Venaxx XL Capsules

- Measured as 3 month average
- Comparative Graph supplied each month

**14. NSAIDs - Measured % items from ePACT**

Reduce prescribing of Diclofenac in favour of Ibuprofen/Naproxen

- Measured as 3 month average
- Comparative Graph supplied each month

**15. Glucosamine/ICaps/Omega 3 - Measured cost per ASTRO PU from ePACT**

Review of these products and other health foods with aim of reducing prescribing in line with CCG average

- Measured as cost per ASTROPU over 3 months
- Comparative graph supplied each month